DK2233156T3 - Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater - Google Patents
Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugaterInfo
- Publication number
- DK2233156T3 DK2233156T3 DK10006638.0T DK10006638T DK2233156T3 DK 2233156 T3 DK2233156 T3 DK 2233156T3 DK 10006638 T DK10006638 T DK 10006638T DK 2233156 T3 DK2233156 T3 DK 2233156T3
- Authority
- DK
- Denmark
- Prior art keywords
- carriers
- pharmaceutical conjugates
- aprotinin polypeptides
- aprotinin
- polypeptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69937505P | 2005-07-15 | 2005-07-15 | |
US75853206P | 2006-01-13 | 2006-01-13 | |
EP06761127A EP1907009A4 (en) | 2005-07-15 | 2006-07-14 | USE OF APROTININ POLYPEPTIDES AS CARRIER IN PHARMACEUTICAL CONJUGATES |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2233156T3 true DK2233156T3 (da) | 2013-08-05 |
Family
ID=37668389
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11010125.0T DK2433653T3 (da) | 2005-07-15 | 2006-07-14 | Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater |
DK10006638.0T DK2233156T3 (da) | 2005-07-15 | 2006-07-14 | Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11010125.0T DK2433653T3 (da) | 2005-07-15 | 2006-07-14 | Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater |
Country Status (16)
Country | Link |
---|---|
US (3) | US8969310B2 (da) |
EP (4) | EP1907009A4 (da) |
JP (3) | JP5436856B2 (da) |
CN (1) | CN101262890B (da) |
AU (1) | AU2006272405B2 (da) |
BR (1) | BRPI0613005A8 (da) |
CA (1) | CA2614687C (da) |
DK (2) | DK2433653T3 (da) |
ES (2) | ES2424242T3 (da) |
HK (1) | HK1148689A1 (da) |
HR (1) | HRP20130720T1 (da) |
PL (1) | PL2233156T3 (da) |
PT (1) | PT2233156E (da) |
RU (2) | RU2422143C2 (da) |
SI (1) | SI2233156T1 (da) |
WO (1) | WO2007009229A1 (da) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1583562E (pt) | 2003-01-06 | 2011-09-19 | Angiochem Inc | Angiopep-1, compostos relacionados, e suas utilizações |
CA2589860A1 (en) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
CA2597958C (en) * | 2005-02-18 | 2019-01-15 | Angiochem Inc. | Molecules for transporting a compound across the blood-brain barrier |
US20090016959A1 (en) * | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
DK2433653T3 (da) | 2005-07-15 | 2019-08-19 | Angiochem Inc | Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater |
AU2006283726C1 (en) | 2005-08-24 | 2015-05-07 | Immunogen, Inc. | Process for preparing maytansinoid antibody conjugates |
CA2666841A1 (en) | 2006-10-19 | 2008-04-24 | Angiochem, Inc. | Compounds for stimulating p-glycoprotein function and uses thereof |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
DK2164866T3 (da) * | 2007-05-29 | 2014-07-28 | Angiochem Inc | Aprotininlignende polypeptider til fremføring af midler, der er konjugeret dertil, til væv |
CA2688344C (en) | 2007-05-29 | 2019-09-03 | Angiochem, Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
MX2010006925A (es) * | 2007-12-20 | 2011-05-02 | Angiochem Inc | Conjugados de polipeptido-acido nucleico y sus usos. |
US8414893B2 (en) | 2007-12-21 | 2013-04-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
EP2279008B1 (en) * | 2008-04-18 | 2019-03-06 | Angiochem Inc. | Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use |
AU2009304505A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
JP2012505637A (ja) * | 2008-10-15 | 2012-03-08 | アンジオケム,インコーポレーテッド | Glp−1アゴニストのコンジュゲート及びその使用 |
CN102307904A (zh) * | 2008-12-05 | 2012-01-04 | 安吉奥开米公司 | 神经降压素或神经降压素类似物的缀合物及其用途 |
CN102300987A (zh) | 2008-12-17 | 2011-12-28 | 安吉奥开米公司 | 膜型-1基质金属蛋白抑制剂及其用途 |
DE102009006228A1 (de) | 2009-01-27 | 2010-07-29 | Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh | Liposomale Zusammensetzung zur Behandlung von Hirnmetastasen |
JP2010229122A (ja) * | 2009-03-06 | 2010-10-14 | Kumamoto Univ | 抗癌剤、医薬、及び癌疾患の検査薬 |
US9173891B2 (en) | 2009-04-20 | 2015-11-03 | Angiochem, Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
SG10201810743WA (en) | 2009-06-03 | 2018-12-28 | Immunogen Inc | Conjugation methods |
RU2012103240A (ru) | 2009-07-02 | 2013-08-10 | Ангиокем Инк. | Мультимерные пептидные конъюгаты и их применение |
EP2588490B1 (en) | 2010-07-02 | 2017-02-22 | Angiochem Inc. | Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
WO2012037687A1 (en) * | 2010-09-23 | 2012-03-29 | Angiochem Inc. | Therapeutic polypeptides and uses thereof |
CN102085157B (zh) * | 2011-01-27 | 2012-02-01 | 中国水产科学研究院黄海水产研究所 | 扇贝抗氧化肽纳米脂质体及其制备方法 |
CN102614524A (zh) * | 2011-02-01 | 2012-08-01 | 复旦大学 | 低密度脂蛋白受体相关蛋白配体多肽修饰的脑肿瘤靶向基因递释复合物 |
SI2691155T1 (sl) | 2011-03-29 | 2019-03-29 | Immunogen, Inc. | Priprava majtanzinoidnih konjugatov protiteles v postopku z enim korakom |
US9687561B2 (en) | 2012-08-14 | 2017-06-27 | Angiochem Inc. | Peptide-dendrimer conjugates and uses thereof |
SG10201702737TA (en) * | 2012-10-04 | 2017-05-30 | Immunogen Inc | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
ES2855169T3 (es) * | 2012-11-12 | 2021-09-23 | Angiochem Inc | Conjugados de polipéptido-anticuerpo derivados de aprotinina |
JP6254692B2 (ja) * | 2013-07-03 | 2017-12-27 | ジ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ | 認知機能不全を治療するための方法 |
CN105452293B (zh) | 2013-07-03 | 2021-03-16 | 首尔大学校产学协力团 | 转化为半胱氨酸的鸡抗体和使用其的位点特异性缀合 |
WO2016014342A2 (en) | 2014-07-21 | 2016-01-28 | Arizona Board Of Regents For The University Of Arizona | Ang-(1-7) derviative oligopeptides and methods for using and producing the same |
US10183055B2 (en) | 2014-07-21 | 2019-01-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications |
GB201502447D0 (en) | 2015-02-13 | 2015-04-01 | Univ Liverpool | Method and apparatus for sample analysis |
ES2826827T3 (es) | 2015-06-15 | 2021-05-19 | Angiochem Inc | Métodos para el tratamiento de carcinomatosis leptomeníngea |
US20210106522A1 (en) | 2018-01-29 | 2021-04-15 | Cognos Therapeutics, Inc. | Intratumoral delivery of bortezomib |
CN111529716B (zh) * | 2020-06-02 | 2021-05-28 | 南方医科大学 | 一种多肽-紫杉醇偶联物及其应用 |
Family Cites Families (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US508697A (en) * | 1893-11-14 | Jar or bottle receiver | ||
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
ES526626A0 (es) * | 1983-10-07 | 1984-10-01 | Jumberca Sa | Mejoras en los alimentadores de hilo para telares circulares de genero de punto dotados de dispositivos listadores. |
ZA871844B (en) | 1986-03-13 | 1988-05-25 | Biotechnology Pty Ltd | Method of assay of inhibin |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4801575A (en) | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4904768A (en) | 1987-08-04 | 1990-02-27 | Bristol-Myers Company | Epipodophyllotoxin glucoside 4'-phosphate derivatives |
GB2208511A (en) | 1987-08-07 | 1989-04-05 | Bayer Ag | Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology |
US4942184A (en) | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
US5632990A (en) | 1988-04-22 | 1997-05-27 | Cancer Research Campaign Tech. Ltd. | Treatment for tumors comprising conjugated antibody A5B7 and a prodrug |
US5258499A (en) | 1988-05-16 | 1993-11-02 | Vestar, Inc. | Liposome targeting using receptor specific ligands |
US5028697A (en) | 1988-08-08 | 1991-07-02 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers |
US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5948634A (en) | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
DE3912638A1 (de) | 1989-04-18 | 1990-10-31 | Bayer Ag | Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel |
US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
US6475781B1 (en) | 1990-05-17 | 2002-11-05 | Dana-Farber Cancer Institute, Inc. | Trans-dominant suppressor genes for oligomeric proteins |
US5714167A (en) | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
US6495513B1 (en) | 1991-03-11 | 2002-12-17 | Curis, Inc. | Morphogen-enhanced survival and repair of neural cells |
US5955444A (en) | 1991-08-09 | 1999-09-21 | Massachusetts Institute Of Technology | Method of inhibiting abnormal tau hyper phosphorylation in a cell |
US5627270A (en) | 1991-12-13 | 1997-05-06 | Trustees Of Princeton University | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
GB9213077D0 (en) | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
WO1994007528A1 (en) | 1992-09-25 | 1994-04-14 | Corvas International, Inc. | Bovine pancreatic trypsin inhibitor derived inhibitors of factor viia-tissue factor complex |
EP0599303A3 (en) | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide conjugate |
MX9307777A (es) | 1992-12-15 | 1994-07-29 | Upjohn Co | 7-HALO-Y 7ß, 8ß-METANO-TAXOLES, USO ANTINEOPLASTICO Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN. |
WO1994019692A1 (en) | 1993-02-18 | 1994-09-01 | The General Hospital Corporation | Alzheimer's disease therapeutics |
WO1996031531A2 (en) | 1995-04-04 | 1996-10-10 | Advanced Bioconcept, Inc. | Fluorescent peptides |
ZA963619B (en) | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
JPH11504938A (ja) | 1995-05-08 | 1999-05-11 | サイオス インク. | クニッツ型プロテアーゼ阻害因子 |
AU5908296A (en) | 1995-05-31 | 1996-12-24 | Fred Hutchinson Cancer Research Center | Compositions and methods for targeted delivery of effector m olecules |
US5780265A (en) | 1995-06-05 | 1998-07-14 | Genentech, Inc. | Kunitz type plasma kallikrein inhibitors |
US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
WO1997033996A2 (en) | 1996-03-11 | 1997-09-18 | Bayer Corporation | Human bikunin |
AU2409397A (en) | 1996-04-24 | 1997-11-12 | Rijksuniversiteit Te Groningen | A prokaryotic protein having functional and structural homology with the uman p-glycoprotein encoded by the mdr-1 gene, nucleic acids encoding and cells expressing said protein |
JP2000509394A (ja) | 1996-05-01 | 2000-07-25 | アンティバイラルズ インコーポレイテッド | 細胞膜を横切って物質を輸送するためのポリペプチド結合体 |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
JP2001503396A (ja) | 1996-10-11 | 2001-03-13 | アルザ コーポレイション | 治療用リポソーム組成物および方法 |
US5948750A (en) | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
JP4116683B2 (ja) | 1997-02-28 | 2008-07-09 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 徐放性局所送達製剤 |
EP0975792B1 (en) * | 1997-03-04 | 2007-10-10 | Savient Pharmaceuticals, Inc. | Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs |
US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
CA2291074C (en) | 1997-05-21 | 2008-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
US6391305B1 (en) | 1997-09-10 | 2002-05-21 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US6093692A (en) | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
US6475481B2 (en) | 1997-11-18 | 2002-11-05 | Canji Inc | Purging of stem cell products |
WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
US5981564A (en) | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
GB9814527D0 (en) * | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
US5922754A (en) * | 1998-10-02 | 1999-07-13 | Abbott Laboratories | Pharmaceutical compositions containing paclitaxel |
MXPA01008699A (es) | 1999-02-24 | 2002-06-21 | Uab Research Foundation | Derivados de taxano para terapia de cancer dirigida. . |
US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
US6136846A (en) | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
DE19953696A1 (de) * | 1999-11-09 | 2001-05-10 | Alexander Cherkasky | Selektive proteolytische Synzyme (SPS) |
CA2307393A1 (en) * | 2000-05-01 | 2001-11-01 | The University Of British Columbia | Ginsenoside chemotherapy |
CA2355334A1 (en) | 2000-10-16 | 2002-04-16 | Procyon Biopharma Inc. | Pharmaceutical preparations and methods for inhibiting tumors |
JP2004536026A (ja) | 2000-11-28 | 2004-12-02 | トランスフォーム ファーマシューティカルズ,インコーポレーティッド. | パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤 |
US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
AU2002254400B2 (en) | 2001-03-23 | 2007-08-09 | Napro Biotherapeutics, Inc. | Molecular conjugates for use in treatment of cancer |
DK2128246T3 (da) | 2001-04-19 | 2014-05-12 | Univ California | Fremgangsmåder og sammensætninger til fremstilling af ortogonale tRNA-aminoacyl-tRNA-syntetasepar. |
EP2147679B1 (en) | 2001-07-25 | 2014-06-25 | Raptor Pharmaceutical, Inc. | Compositions for blood-brain barrier transport |
US20040161776A1 (en) | 2001-10-23 | 2004-08-19 | Maddon Paul J. | PSMA formulations and uses thereof |
US7192921B2 (en) | 2001-11-08 | 2007-03-20 | The Burnham Institute | Peptides that home to tumor lymphatic vasculature and methods of using same |
GEP20063806B (en) * | 2001-12-20 | 2006-04-25 | Bristol Myers Squibb Co | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability |
CA2474283A1 (en) | 2002-02-07 | 2003-08-14 | Yissum Research Development Company Of The Hebrew University In Jerusale M | Amino acid sequences capable of facilitating penetration across a biological barrier |
US6881829B2 (en) | 2002-04-26 | 2005-04-19 | Chimeracom, L.L.C. | Chimeric hybrid analgesics |
US20040077540A1 (en) | 2002-06-28 | 2004-04-22 | Nastech Pharmaceutical Company Inc. | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US20040102369A1 (en) | 2002-11-27 | 2004-05-27 | The Regents Of The University Of California | Transport of basic fibroblast growth factor across the blood brain barrier |
US7388079B2 (en) | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
PT1583562E (pt) * | 2003-01-06 | 2011-09-19 | Angiochem Inc | Angiopep-1, compostos relacionados, e suas utilizações |
WO2005046569A2 (en) * | 2003-04-08 | 2005-05-26 | Biotempt B.V. | Pharmaceutical compositions for the treatment of sars |
KR101424624B1 (ko) | 2003-05-14 | 2014-07-31 | 이뮤노젠 아이엔씨 | 약물 콘쥬게이트 조성물 |
WO2004108071A2 (en) | 2003-06-05 | 2004-12-16 | Salk Institute For Biological Studies | Targeting polypeptides to the central nervous system |
JP5624256B2 (ja) | 2003-06-20 | 2014-11-12 | ラプター・ファーマシューティカル・インコーポレイテッド | 脳および他の組織への治療化合物の送達 |
US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
WO2005014625A1 (ja) | 2003-08-08 | 2005-02-17 | Tissue Targeting Japan Inc. | 脳移行活性を有するポリペプチド、およびその利用 |
WO2005021579A2 (en) * | 2003-08-28 | 2005-03-10 | Biorexis Pharmaceutical Corporation | Epo mimetic peptides and fusion proteins |
US20050058702A1 (en) | 2003-09-17 | 2005-03-17 | Ben-Sasson Shmuel A. | Compositions capable of facilitating penetration across a biological barrier |
US20050208095A1 (en) | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
US7208174B2 (en) | 2003-12-18 | 2007-04-24 | Hoffmann-La Roche Inc. | Liposome compositions |
AU2005327906B2 (en) | 2004-07-21 | 2010-05-13 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
AU2005266184A1 (en) | 2004-07-26 | 2006-02-02 | Asterion Limited | Linkers |
DE602005015994D1 (de) | 2004-09-29 | 2009-09-24 | Childrens Memorial Hospital | siRNA-VERMITTELTES GEN-SILENCING VON ALPHA-SYNUKLEIN |
US20090016959A1 (en) | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
CA2597958C (en) | 2005-02-18 | 2019-01-15 | Angiochem Inc. | Molecules for transporting a compound across the blood-brain barrier |
PL3248600T3 (pl) | 2005-02-18 | 2020-09-07 | Abraxis Bioscience, Llc | Połączenia i sposoby podawania środków terapeutycznych i terapia skojarzona |
EP1888121A2 (en) | 2005-05-12 | 2008-02-20 | Tapestry Pharmaceuticals, Inc. | Anticancer targeted conjugates comprising a succinyl or glutaryl linker |
US8877714B2 (en) | 2005-06-14 | 2014-11-04 | Raptor Pharmaceutical Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof |
DK2433653T3 (da) | 2005-07-15 | 2019-08-19 | Angiochem Inc | Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater |
WO2007012004A2 (en) | 2005-07-19 | 2007-01-25 | The Board Of Trustees Of The University Of Illinois | Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof |
GB0517092D0 (en) | 2005-08-19 | 2005-09-28 | Novartis Ag | New compositions containing taxane derivatives |
JP2009507852A (ja) | 2005-09-08 | 2009-02-26 | エムディーアールエヌエー,インコーポレイテッド | リボ核酸の細胞への送達用医薬組成物 |
US9062126B2 (en) | 2005-09-16 | 2015-06-23 | Raptor Pharmaceuticals Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof |
US8142781B2 (en) | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
KR20080086440A (ko) | 2005-11-01 | 2008-09-25 | 알닐람 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 RNAi 억제 |
AR054215A1 (es) | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
JP5102833B2 (ja) | 2006-07-24 | 2012-12-19 | バイオレクシス ファーマシューティカル コーポレーション | エキセンディン融合タンパク質 |
WO2008036682A2 (en) | 2006-09-18 | 2008-03-27 | Raptor Pharmaceutical Inc. | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates |
CA2666841A1 (en) | 2006-10-19 | 2008-04-24 | Angiochem, Inc. | Compounds for stimulating p-glycoprotein function and uses thereof |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
CA2688344C (en) | 2007-05-29 | 2019-09-03 | Angiochem, Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
US8802631B2 (en) | 2007-09-17 | 2014-08-12 | Ludwig Institute For Cancer Research Ltd. | Peptides and methods for the treatment of gliomas and other cancers |
WO2009070597A2 (en) | 2007-11-26 | 2009-06-04 | Armagen Technologies, Inc. | Fusion proteins for delivery of gdnf to the cns |
MX2010006925A (es) | 2007-12-20 | 2011-05-02 | Angiochem Inc | Conjugados de polipeptido-acido nucleico y sus usos. |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
CA2713872A1 (en) | 2008-02-21 | 2009-08-27 | Burnham Institute For Medical Research | Methods and compositions related to peptides and proteins with c-terminal elements |
EP2279008B1 (en) | 2008-04-18 | 2019-03-06 | Angiochem Inc. | Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use |
AU2009304505A1 (en) * | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
JP2012505637A (ja) | 2008-10-15 | 2012-03-08 | アンジオケム,インコーポレーテッド | Glp−1アゴニストのコンジュゲート及びその使用 |
WO2010063123A1 (en) | 2008-12-05 | 2010-06-10 | Angiochem Inc. | Leptin and leptin analog conjugates and uses thereof |
WO2010063124A1 (en) | 2008-12-05 | 2010-06-10 | Angiochem Inc. | Peptide therapeutic conjugates and uses thereof |
CN102307904A (zh) | 2008-12-05 | 2012-01-04 | 安吉奥开米公司 | 神经降压素或神经降压素类似物的缀合物及其用途 |
CN102300987A (zh) | 2008-12-17 | 2011-12-28 | 安吉奥开米公司 | 膜型-1基质金属蛋白抑制剂及其用途 |
US9173891B2 (en) * | 2009-04-20 | 2015-11-03 | Angiochem, Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
US20100284921A1 (en) | 2009-05-08 | 2010-11-11 | Temple University - Of The Commonwealth System Of Higher Education | Targeted nanoparticles for intracellular cancer therapy |
US20120196803A1 (en) | 2009-06-11 | 2012-08-02 | Angiochem Inc. | Fusion proteins for delivery of gdnf and bdnf to the central nervous system |
RU2012103240A (ru) | 2009-07-02 | 2013-08-10 | Ангиокем Инк. | Мультимерные пептидные конъюгаты и их применение |
BR112012000908A2 (pt) | 2009-07-14 | 2019-09-24 | Mayo Found Medical Education & Res | liberação de agentes ativos através da barreira hematoencefálica mediada por peptídeo em associação não covalente |
US20120277158A1 (en) | 2009-10-06 | 2012-11-01 | Angiochem Inc. | Compositions and methods for the transport of therapeutic agents |
US8530429B2 (en) | 2009-11-24 | 2013-09-10 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
WO2011153642A1 (en) | 2010-06-10 | 2011-12-15 | Angiochem Inc. | Leptin and leptin analog conjugates and fusion proteins and uses thereof |
EP2588490B1 (en) | 2010-07-02 | 2017-02-22 | Angiochem Inc. | Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
WO2012037687A1 (en) | 2010-09-23 | 2012-03-29 | Angiochem Inc. | Therapeutic polypeptides and uses thereof |
CN103561726A (zh) | 2010-11-18 | 2014-02-05 | 通用医疗公司 | 用于癌症治疗的抗高血压剂的新型组合物和用途 |
WO2013056096A1 (en) | 2011-10-13 | 2013-04-18 | Angiochem Inc. | Polypeptide-opioid conjugates and uses thereof |
CN104145015A (zh) | 2011-12-01 | 2014-11-12 | 安吉奥开米公司 | 靶向的溶酶体酶化合物 |
CA2857548A1 (en) | 2011-12-01 | 2013-06-06 | Angiochem Inc. | Targeted enzyme compounds and uses thereof |
WO2013185235A1 (en) | 2012-06-15 | 2013-12-19 | Angiochem Inc. | Targeted iduronidase compounds |
US9687561B2 (en) | 2012-08-14 | 2017-06-27 | Angiochem Inc. | Peptide-dendrimer conjugates and uses thereof |
WO2014026286A1 (en) | 2012-08-14 | 2014-02-20 | Angiochem Inc. | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
ES2855169T3 (es) | 2012-11-12 | 2021-09-23 | Angiochem Inc | Conjugados de polipéptido-anticuerpo derivados de aprotinina |
GB201220474D0 (en) | 2012-11-14 | 2012-12-26 | Sagetis Biotech Sl | Polypeptides |
CA2892763A1 (en) | 2012-11-30 | 2014-06-05 | Angiochem Inc. | Targeted iduronate-2-sulfatase compounds |
HK1179821A2 (en) | 2013-05-28 | 2013-10-04 | Chit Shun Catv Equipment Ltd | High voltage discharge protection device and radio frequency transmission apparatus using the same |
US20160367691A1 (en) | 2013-06-06 | 2016-12-22 | Angiochem Inc. | Targeted enzyme compounds and uses thereof |
WO2014194428A1 (en) | 2013-06-06 | 2014-12-11 | Angiochem Inc. | Targeted heparan sulfatase compounds |
-
2006
- 2006-07-14 DK DK11010125.0T patent/DK2433653T3/da active
- 2006-07-14 CA CA2614687A patent/CA2614687C/en not_active Expired - Fee Related
- 2006-07-14 BR BRPI0613005A patent/BRPI0613005A8/pt not_active Application Discontinuation
- 2006-07-14 EP EP06761127A patent/EP1907009A4/en not_active Withdrawn
- 2006-07-14 PT PT100066380T patent/PT2233156E/pt unknown
- 2006-07-14 PL PL10006638T patent/PL2233156T3/pl unknown
- 2006-07-14 EP EP11010071A patent/EP2471555A3/en not_active Withdrawn
- 2006-07-14 JP JP2008520685A patent/JP5436856B2/ja active Active
- 2006-07-14 SI SI200631629T patent/SI2233156T1/sl unknown
- 2006-07-14 ES ES10006638T patent/ES2424242T3/es active Active
- 2006-07-14 CN CN200680033365.8A patent/CN101262890B/zh not_active Expired - Fee Related
- 2006-07-14 EP EP11010125.0A patent/EP2433653B1/en active Active
- 2006-07-14 WO PCT/CA2006/001165 patent/WO2007009229A1/en active Search and Examination
- 2006-07-14 DK DK10006638.0T patent/DK2233156T3/da active
- 2006-07-14 RU RU2008105677/15A patent/RU2422143C2/ru active
- 2006-07-14 AU AU2006272405A patent/AU2006272405B2/en not_active Ceased
- 2006-07-14 EP EP10006638.0A patent/EP2233156B1/en active Active
- 2006-07-14 ES ES11010125T patent/ES2744225T3/es active Active
-
2007
- 2007-05-30 US US11/807,917 patent/US8969310B2/en active Active
-
2011
- 2011-03-23 HK HK11102916.4A patent/HK1148689A1/xx not_active IP Right Cessation
- 2011-04-19 RU RU2011115418/15A patent/RU2011115418A/ru not_active Application Discontinuation
-
2012
- 2012-10-18 JP JP2012230853A patent/JP2013047249A/ja not_active Withdrawn
-
2013
- 2013-08-01 HR HRP20130720TT patent/HRP20130720T1/hr unknown
-
2015
- 2015-03-02 US US14/635,856 patent/US9713646B2/en active Active
- 2015-06-03 JP JP2015112969A patent/JP2015163641A/ja active Pending
-
2017
- 2017-06-30 US US15/639,758 patent/US20180221497A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2433653T3 (da) | Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater | |
FR22C1008I2 (fr) | Composition immunogène | |
RU2398586C3 (ru) | Фармацевтическая композиция | |
BRPI0511900A (pt) | composições farmacêuticas | |
DK1940467T3 (da) | Lægemiddelsammensætning med langvarig frigivelse | |
DK1931702T3 (da) | Silkeproteiner | |
DE602005007194D1 (de) | Schaltschlepphebelanordnung | |
BRPI0614464A2 (pt) | preparação cosmética | |
DK1957073T3 (da) | Lægemiddel | |
ES2845143T8 (es) | Composición de trombina estable | |
DK1868586T3 (da) | Antiinflammatorisk formulering | |
DE602006006937D1 (de) | Hosenträger | |
DE602006003199D1 (de) | Saugfähiger artikel | |
ITMI20051569A1 (it) | Composizione cicatrizzante | |
DE602005017191D1 (de) | Geruchsreduzierte waschstück-zusammensetzung | |
DK1968623T3 (da) | Bacteriocin-inducer-peptider | |
FR2885520B1 (fr) | Composition cosmetique | |
FR2885521B1 (fr) | Composition cosmetique | |
DK1784174T3 (da) | Famaceutisk sammensætning omfattende gabapentin | |
ITMI20042232A1 (it) | Composizione farmaceutica contenente clozapina | |
FR2871686B1 (fr) | Composition anti-decoloration | |
ITMI20040943A1 (it) | Composizione farmaceutica cicatrizzante | |
FI20065208A0 (fi) | Peptidikonjugaatteja | |
FR2885801B1 (fr) | Composition cosmetique | |
ITMI20051721A1 (it) | Composizione farmaceutica cicatrizzante |